A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

195

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions

Vasomotor Symptoms

Interventions

DRUG

HS-10384 tablet Dose 1

Administered orally QD

DRUG

HS-10384 tablet Dose 2

Administered orally QD

DRUG

HS-10384-matched placebo tablets

Administered orally QD

Trial Locations (1)

Chinese Academy of Medical Sciences (CAMS)Peking Union Medical College (PUMC), Shanghai

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06393673 - A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women | Biotech Hunter | Biotech Hunter